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METABOLOMICS REVEALS DIFFERENCES IN METABOLIC PATHWAYS
PREDICTIVE OF RECOVERY OF RENAL FUNCTION AFTER LIVER
TRANSPLANTATION
Ashwani K. Singal, Landon Wilson, Stephen Barnes
Background: Acute kidney injury (AKI) is common in patients with cirrhosis, and impacts
pre and post liver transplant (LT) outcomes. In our previous study, examination of known
urinary protein biomarkers of AKI among urine samples collected prior to LT did not predict
recovery of renal function after LT. In the present study, untargeted metabolomics analysis
was applied to the urines, to determine whether metabolite biomarkers/pathways were
capable of distinguishing recovery versus non-recovery of renal function after LT alone
among patients with liver cirrhosis. Methods: Metabolites in deproteinized urines of 29
patients (16 F) were analyzed by nanoLC-MS/MS on an Eksigent C18 ChipLC column (15
cm x 200 µm ID) using a 20 min 0-95% linear gradient of acetonitrile on 0.1% formic acid
at 45oC. Data were recorded in negative ion and positive modes. each cycle consisted of a
250 ms hi-res TOF-MS, followed by twenty 50 ms MSMS selected precursor ions. Collected
data were processed using XCMSonline. Aligned metabolite ions and their peaks were
subjected to statistical analysis with Metaboanalyst 3.0 with total ion current normalization
and Pareto scaling. Normalized data were also subjected to pathway and module analysis
with Mummichog 1.0.9. Results: Initial multivariate Partial Least Squares Discriminant
Analysis (PLSDA) on recovery versus non-recovery of renal function demonstrated two
groups to be well separated. Mummichog analysis showed statistical differences in steroid
metabolism, oxidized fatty acids and squalene biosynthesis. In women, metabolites in the
lysine metabolism pathway, trimethylammoniobutanal, trimethylammoniobutanoate and car-
nitine were observed. Two enzymes in carnitine pathway (N ε-Trimethyllysine hydroxylase
and γ-butyrobetaine hydroxylase) are alpha-ketoglutarate (αKG)-dependent. A second key
metabolite was thiamine, which as pyrophosphate is an essential cofactor for 2-oxoglutarate
dehydrogenase, to produce αKG. The metabolies in the squalene pathway were farnesyl
diphosphate, geranyl diphosphate and geranylgeranyl diphosphate. The latter forms covalent
adducts with Cys residues on the Rho GTPases, RhoA and Rac1, and causes mitochondrial
dysfunction which may lead to αKG deficiency. These data suggest that an αKG deficiency
may be a rationale for the onset of AKI. Other metabolic pathways affected in women
were in estrogen quinone formation. In men, principal pathways affected were in steroid
metabolism (negative and positive modes) and fatty acid oxidation (positive mode). Conclu-
sion: Kidney among cirrhosis patients is vulnerable to modifications to key pathways, which
may be distinctive among patients who recover their renal function after LT alone compared
to those who are unable to recover the renal function. These biomarkers may have clinical
utility as basis for optimal allocation of simultaneous liver kidney transplants.
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TISSUE RENIN-ANGIOTENSIN SYSTEM IN THE KIDNEY OF ASCITIC
CIRRHOSIS: AN INNOCENT BYSTANDER OR A PROTAGONIST?
Giovanni Sansoe, Manuela Aragno, Raffaella Mastrocola, Maurizio Parola
Introduction. In liver cirrhosis, kidney local renin-angiotensin system (RAS) deserves scru-
tiny and includes: conversion of angiotensin I into angiotensin II (Ang-II) by ACE and
chymase; binding of renin and prorenin to their tissue receptor (RPR), leading to local
generation of angiotensin I and Ang-II; conversion of Ang-II by ACE2 into natriuretic
peptide angiotensin1-7; degradation of the latter to angiotensin1-4 by neprilysin. Changes
in expression of these enzymes and receptors may affect renal levels of sodium-retentive
(Ang-II) and natriuretic (angiotensin1-7) peptides. Aims. To assess, in ascitic rats' kidney,
content and immunolocation of RPR, ACE, chymase, neprilysin, Ang-II and angiotensin1-
7. Methods. Healthy rats (group G1) and rats with ascitic cirrhosis due to CCl4 (G2) were
studied. Kidney content of ACE, chymase, RPR, ACE2, neprilysin, Ang-II, angiotensin1-7
and plasma levels of Ang-II, direct renin (DR), plasma renin activity (PRA) were measured.
DR is quantified through monoclonal antibodies that bind both active renin and prorenin,
and therefore plasma concentrations of prorenin can be derived from the ratio DR/PRA.
Results. DR/PRA ratios were 3.3 ± 0.8 and 7.9 ± 1.6 in healthy and ascitic rats, respectively
(P<0.03), showing more prorenin in ascitic rats. In G2, Ang-II was higher than normal in
plasma (P<0.01) but especially in renal tissue (1150 ± 199 vs. 78 ± 22 pg/mg kidney protein,
P<0.001). Kidney content of ACE, chymase, ACE2 and neprilysin was significantly higher,
but RPRrs significantly lower, in ascitic than in healthy rats. The ratio Ang-II/Angiotensin1-
7 in kidneys rose from 1.3 ± 0.2 in G1 to 5.3 ± 0.4 in G2 (P<0.03). Conclusions. In ascitic
cirrhosis: a) the contribution of ACE and chymase to renal Ang-II synthesis seems stronger
than that of RPRs, despite increased plasma prorenin; b) the kidney shows an imbalance in
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favour of the production of anti-natriuretic Ang-II because overexpressed neprilysin finally
degrades ACE2-generated angiotensin1-7.
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TRENDS IN THE PREVALENCE OF PORTAL VEIN THROMBOSIS AND
ASSOCIATED MORTALITY IN CIRRHOSIS: ANALYSIS OF A NATIONALLY
REPRESENTATIVE INPATIENT COHORT
Josephine Cool, Russell Rosenblatt, Sonal Kumar, Catherine Lucero, Brett Fortune, Carl V.
Crawford, Arun Jesudian
BACKGROUND Portal vein thrombosis (PVT) is common in cirrhosis and has been associated
with poor survival. Increased recognition of the associated clinical consequences has led
providers to more aggressively identify and treat PVT in these patients in recent years. To
date, no study has analyzed the trend of the prevalence of PVT and its effect on mortality
in hospitalized decompensated cirrhotics. METHODS This study was performed using the
Nationwide Inpatient Sample (NIS) from 1998-2014, a large, nationally-representative data-
base of hospital discharges. All inpatients older than 18 years of age with decompensated
cirrhosis or evidence of clinically-significant portal hypertension were identified using a
validated algorithm. Those with hepatocellular carcinoma were excluded. The primary out-
comes were the trend in prevalence and mortality associated with PVT. The secondary
outcomes were the identification of risk factors in the development of PVT and its effect
on acute kidney injury and hepatorenal syndrome. Multivariate logistic regression was used
to correct for conditions known to affect mortality in cirrhotics. RESULTS We identified
3,045,098 patients, of which 48,438, 1.6%, had PVT. PVT prevalence increased from 0.7%
in 1998 to 2.4% in 2014. Mortality in cirrhotics with PVT fluctuated but overall declined
over the same time period, decreasing from 11.9% in 1998 to 9.1% in 2014. In univariate
analysis, PVT was associated with increased risk of mortality (OR 1.24, 95% CI 1.11-1.39,
p<0.001). PVT was associated with an increased mortality even when controlling for age,
gender, ascites, infection, encephalopathy, and Elixhauser comorbidity index (OR 1.17, 95%
CI 1.10-1.25, p<0.001). Multivariate logistic regression demonstrated that PVT significantly
increased the risk of acute kidney injury (OR 1.69, 95% CI 1.61-1.77, p<0.001) and
hepatorenal syndrome (OR 1.56, 95% CI 1.45-1.66, p<0.001). CONCLUSIONS Our findings
demonstrate that while the prevalence of PVT is rising in hospitalized cirrhotics, mortality
in patients with cirrhosis and PVT is decreasing despite increased risk of acute kidney injury
and hepatorenal syndrome. Decreased mortality over time might be related to more aggressive
anticoagulation of PVT and/or improved inpatient care of decompensated cirrhotics. The
causes underlying these trends warrant further study.
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THE ASSOCIATION BETWEEN PORTAL VEIN THROMBOSIS AND OTHER
VENOUS THROMBOEMBOLISM IN CIRRHOSIS: ANALYSIS OF A
NATIONALLY REPRESENTATIVE INPATIENT COHORT
Josephine Cool, Russell Rosenblatt, Sonal Kumar, Catherine Lucero, Brett Fortune, Carl V.
Crawford, Arun Jesudian
BACKGROUND Patients with cirrhosis are known to be at increased risk of portal vein
thrombosis (PVT) in the setting of portal hypertension. Recent data suggest that rebalanced
hemostasis also places cirrhotics at an almost two-fold increased risk of additional venous
thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism
(PE). As there is little evidence identifying the association between PVT and VTE in decompen-
sated cirrhotics, this study examined this interaction, and the outcomes related to multiple
thrombotic events in this population. METHODS This study was performed using the
Nationwide Inpatient Sample (NIS) from 1998-2014, a large, nationally-representative data-
base of hospital discharges. All patients older than 18 years of age with decompensated
cirrhosis or evidence of clinically-significant portal hypertension were identified using a
validated algorithm. Those with hepatocellular carcinoma were excluded. The primary out-
come was the association between PVT and DVT/PE. The secondary outcomes were the
effect of DVT/PE on mortality in cirrhotics with PVT and identification of risk factors in the
development of PVT and DVT/PE. Multivariate logistic regression was employed to control
for conditions known to affect outcomes in cirrhosis. Disease states were identified using ICD-
9 codes. RESULTS We identified 3,045,098 patients with cirrhosis excluding hepatocellular
carcinoma (HCC), of which 48,438, or 1.6%, had PVT. Patients with PVT were more likely
to have an underlying DVT or PE than patients without PVT (2.5% vs. 0.9%, p<0.001). In
univariate analysis, PVT was associated with an increased risk of DVT/PE (OR 2.93, 95%
CI 2.57-3.34, p<0.001). This association persisted in multivariate analysis controlling for
age, gender, race, hypercoagulable state such as pregnancy or myeloproliferative disorder,
recent major operation or non-primary liver cancer (OR 2.16, 95% CI 1.81-2.59, p<0.001).
In multivariate analysis, patients with PVT did not have a significantly higher inpatient
mortality if they had a DVT/PE. Patients with PVT were more likely to have DVT/PE if they
had a hypercoagulable disorder (OR 4.05, 95% 2.56-6.42, p<0.001), recent major operation
(OR 3.47, 95% CI 2.58-4.66, p<0.001), and acute kidney injury (OR 1.48, 95% CI 1.10-
1.99, p=0.01). CONCLUSIONS Our study noted that VTE is more common in hospitalized
